Xencor (NASDAQ:XNCR) Reaches New 12-Month Low – Here’s Why

Xencor, Inc. (NASDAQ:XNCR) shares reached a new 52-week low on Monday . The company traded as low as $12.69 and last traded at $12.89, with a volume of 723182 shares changing hands. The stock had previously closed at $12.87.

Analyst Ratings Changes

A number of research firms have recently weighed in on XNCR. StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Wells Fargo & Company reduced their price target on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Finally, Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and raised their price target for the company from $20.00 to $30.00 in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Xencor presently has an average rating of “Moderate Buy” and an average price target of $34.38.

Xencor Trading Down 2.8 %

The firm’s 50-day moving average is $16.92 and its 200 day moving average is $20.40. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $889.23 million, a price-to-earnings ratio of -3.94 and a beta of 0.74.

Xencor (NASDAQ:XNCR) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $52.79 million for the quarter, compared to the consensus estimate of $17.14 million. On average, equities analysts predict that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xencor

Several hedge funds have recently added to or reduced their stakes in XNCR. Point72 Asset Management L.P. boosted its position in Xencor by 147.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 3,120,229 shares of the biopharmaceutical company’s stock worth $62,748,000 after buying an additional 1,858,440 shares during the period. RTW Investments LP raised its holdings in Xencor by 317.9% during the 4th quarter. RTW Investments LP now owns 2,402,883 shares of the biopharmaceutical company’s stock worth $55,218,000 after purchasing an additional 1,827,883 shares during the last quarter. BVF Inc. IL raised its holdings in Xencor by 169.3% during the 4th quarter. BVF Inc. IL now owns 2,288,760 shares of the biopharmaceutical company’s stock worth $52,596,000 after purchasing an additional 1,438,760 shares during the last quarter. Nuveen Asset Management LLC raised its holdings in Xencor by 452.4% during the 4th quarter. Nuveen Asset Management LLC now owns 837,082 shares of the biopharmaceutical company’s stock worth $19,236,000 after purchasing an additional 685,557 shares during the last quarter. Finally, Finepoint Capital LP bought a new position in Xencor during the 4th quarter worth approximately $15,167,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.